Kirhan Özgürdal

Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI)

Marcia S. Brose, Johannes W. A. Smit, Chia‐Chi Lin et al. · Thyroid · 2022 · 21 citations · Full text

Medicine, Oncology, Pharmacology +9

Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase III RESORCE trial

Jordi Bruix, María Reig, Philippe Merle et al. · Annals of Oncology · 2019 · 17 citations · Full text

Medicine, Oncology, Molecular Oncology +11

Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States

Amit G. Singal, Kirhan Özgürdal, Xiaozhou Fan et al. · Cancers · 2023 · 17 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +13

Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety

Philippe Merle, Masatoshi Kudo, Stanimira Krotneva et al. · Liver Cancer · 2022 · 16 citations · Full text

Medicine, Oncology, Pharmacology +15

Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study

Faysal Dane, Kirhan Özgürdal, Şuayib Yalçın et al. · BMJ Open · 2020 · 15 citations · Full text

Medicine, Oncology, Pharmacology +15